COVID salivary diagnostics: A comparative technical study.
Hanh Nguyen-KimChristiane BeckmannMaurice RedondoJérémy ZilioxVirginie ValletKarin Berger-SturmJan Von OverbeckLavinia Alberi AuberPublished in: Journal of medical virology (2022)
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, molecular diagnostics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have taken center stage in the detection of infected individuals for isolation purposes but also in the mass surveillance as a preventive strategy to contain the virus spread. While nasopharyngeal swabs (NPS) have remained the golden standard substrate, salivary diagnostic for SARS-CoV-2 has been proposed as an alternative and noninvasive measure in vulnerable individuals. Nevertheless, there is a widespread assumption that salivary reverse-transcription polymerase chain reaction (RT-PCR) does not match the quality of testing using NPS and particular care should be taken in respect to food or beverage intake, when sampling saliva. Our study indicates that without any precaution in the selection of 190 patients, nor restriction over the time window of sampling, there is 99% match in the COVID-19 positivity between NPS and saliva when using RT-PCR, with a reported Delta in thermal cycles (Cts) values for the viral genes Envelope (E) and Open reading frame 1ab (Orf1ab) between 0 and 2, a 98.7% sensitivity and 100% specificity. This high accuracy is maintained in pooling configurations that can be used for mass-testing purposes in professional and educational settings. The further advantage to using crude saliva as compared to NPS or mouthwash is that direct methods yield robust results. Overall, our study validates and promotes the use of salivary diagnostic for COVID-19 eliminating the need of a medical practitioner for the sampling, resolving the unpleasantness of the NPS intervention and empowering the patient to do self-testing in times of need.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- healthcare
- randomized controlled trial
- transcription factor
- ejection fraction
- minimally invasive
- end stage renal disease
- risk assessment
- dna methylation
- body mass index
- genome wide
- newly diagnosed
- case report
- physical activity
- health insurance
- pain management